Funds boost from Novo Nordisk

Novo Nordisk, the Danish copmany best known for diabetes treatments, and which has over 42,000 employees globally, has been tipped for additional annual sales of up to $10bn within five years of launch of an oral version of its Semaglutide medication – if it is able to make a pill.

The forecast has come from analysts at Deutsche Bank, as reported in Danish business daily Børsen.

The treatment has been reported by the company as resulting in “significantly improved glycaemic control compared to placebo, as add-on to basal insulin alone or in combination with metformin, in adults with a mean type 2 diabetes duration of 13 years.”

Analysing the Austrian, German and Italian mutual fund universes on FE for funds with exposure to Novo Nordisk has thrown up the following five that have exhibited best returns over a three year period.

Funds – Return in euro % 1m 3m 6m 1yr 3yr 5yr 10yr
BlackRock SF European Opportunities Extension E2 EUR in EU 0.37 7.84 8.19 14.51 87.77 218.11
ComStage STOXX ® Europe 600 Health Care NR UCITS ETF in EU 1.45 2.38 6.74 -1.77 41.59 117.68
Flossbach von Storch Global Quality R TR in EU 1.12 4.79 7.20 15.72 40.89 89.00
JPM Europe Strategic Growth A Dis EUR TR in EU 0.14 5.85 6.72 5.38 45.71 130.26 74.53
Threadneedle Global Select Ret GBP in EU 1.73 7.69 7.19 9.43 42.86 100.67 81.20

Novo Nordisk is the biggest single holding in BlackRock’s fund, according to FE data.

It accounts for some 8.4% of the STOXX healthcare fund, 4.6% of the Flossback fund, 2.6% of the JPM Europe fund, and 2.1% of the Threadneedle fund.

Since January 2000, the company’s share price has risen from around DKK18 to around DKK400 by early in 2016, before the price edged off to its current level around DKK290.







Jonathan Boyd
Editorial Director of Open Door Media Publishing Ltd, and Editor of InvestmentEurope.

Read more from Jonathan Boyd

Close Window
View the Magazine

You need to fill all required fields!